EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation Who Switched from Warfarin to Direct Oral Anticoagulants in Medicare Population

Nipun Atreja, Anandkumar Dubey, Amiee Kang, Jenny Jiang, Melissa Hagan, Abimbola Michael-Asalu, Dong Cheng, Steven Deitelzweig

Advances in Therapy · 2025

DOI: 10.1007/s12325-024-03099-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Therapy, 2025. Verfasst von Nipun Atreja und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Myers Squibb, Lawrenceville, NJ, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Warfarin, Anticoagulants, Stroke. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Atrial fibrillation (AF), a common heart rhythm abnormality, is linked to a higher risk of stroke. Traditionally, warfarin has been the primary anticoagulation treatment for reducing the stroke risk. The new standard of treatment by direct oral anticoagulants (DOACs) offers greater benefits including improved efficacy and fewer adverse effects with reduced monitoring. This study aims to evaluate the risk of stroke/systemic embolism (SE) and major bleeding (MB) among patients with AF who switched from warfarin to DOACs. METHODS: This study utilized Medicare data to conduct a retrospective analysis of patients with non-valvular atrial fibrillation (NVAF) who switched from warfarin to DOACs between January 1, 2012, and December 31, 2019. Patients with NVAF aged 65 and older who switched from warfarin and had continuous health plan enrollment were included. Descriptive statistics, propensity score matching (PSM), and Cox proportional hazard (PH) models were utilized to compare the outcomes and assess risks of SE and MB across the DOAC cohorts. RESULTS: Among 1,843,495 patients with NVAF on warfarin, 171,700 switched to DOACs within 90 days of discontinuation (apixaban: 90,850; rivaroxaban: 67,698; dabigatran: 12,900). The mean follow-up period across DOAC cohorts ranged from 552 to 628 days. After PSM, apixaban showed significantly lower rates of stroke/SE compared to dabigatran (2.99% vs. 3.98%, p < 0.0001) and rivaroxaban (3.08% vs. 3.80%, p < 0.0001). MB rates were also lower with apixaban versus dabigatran (4.29% vs. 5.57%, p < 0.0001) and rivaroxaban (4.07% vs. 6.35%, p < 0.0001). Cox PH models confirmed these findings, with apixaban demonstrating lower risks of stroke/SE [hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.72-0.96 vs. dabigatran; HR 0.91, 95% CI 0.85-0.96 vs. rivaroxaban] and MB (HR 0.79, 95% CI 0.71-0.89 vs. dabigatran; HR 0.68, 95% CI 0.65-0.72 vs. rivaroxaban). CONCLUSION: The risk of stroke/SE and MB varies significantly among patients with NVAF switching from warfarin to different DOACs, with apixaban presenting the lowest risk compared to dabigatran and rivaroxaban.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationWarfarinAnticoagulantsStrokeFactor Xa InhibitorsHumansUnited StatesAgedMaleMedicareFemaleRetrospective StudiesAged, 80 and overHemorrhageAdministration, OralRivaroxabanPyrazolesEmbolismDabigatranDrug SubstitutionPyridones

Stichwörter der Autor:innen

ApixabanAtrial fibrillationDabigatranDirect oral anticoagulantsRivaroxabanStrokeSwitchSystemic embolismWarfarin

Substanzen

WarfarinAnticoagulantsRivaroxabanPyrazolesapixabanDabigatranFactor Xa InhibitorsPyridones

Autor:innen und Institutionen

  • Bristol Myers Squibb, Lawrenceville, NJ, USA.
  • Bristol Myers Squibb, Lawrenceville, NJ, USA. anandkumar.dubey@bms.com.
  • STATinMED LLC, Dallas, TX, USA.
  • Bristol Myers Squibb, Lawrenceville, NJ, USA. dong.cheng@bms.com.
  • Department of Hospital Medicine, Ochsner Health System, New Orleans, LA, 70121, USA.

Zitieren

APA

Atreja, N., Dubey, A., Kang, A., Jiang, J., Hagan, M., Michael-Asalu, A., Cheng, D., & Deitelzweig, S. (2025). Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation Who Switched from Warfarin to Direct Oral Anticoagulants in Medicare Population. Advances in Therapy. https://doi.org/10.1007/s12325-024-03099-y

Vancouver

Atreja N, Dubey A, Kang A, Jiang J, Hagan M, Michael-Asalu A, et al. Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation Who Switched from Warfarin to Direct Oral Anticoagulants in Medicare Population. Advances in Therapy. 2025. doi:10.1007/s12325-024-03099-y

BibTeX
@article{Atreja2025,
  author = {Atreja, Nipun and Dubey, Anandkumar and Kang, Amiee and Jiang, Jenny and Hagan, Melissa and Michael-Asalu, Abimbola and Cheng, Dong and Deitelzweig, Steven},
  title = {Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation Who Switched from Warfarin to Direct Oral Anticoagulants in Medicare Population},
  journal = {Advances in Therapy},
  year = {2025},
  doi = {10.1007/s12325-024-03099-y}
}
Kostenlos starten →